Abadir Sylvia, Boudjemline Younes, Rey Christian, Petit Jérome, Sassolas François, Acar Philippe, Fraisse Alain, Dauphin Claire, Piechaud Jean-François, Chantepie Alain, Lusson Jean-René
Service de cardiologie pédiatrique, hôpital des Enfants, 330, avenue de Grande-Bretagne, 31026 Toulouse, France.
Arch Cardiovasc Dis. 2009 Jun-Jul;102(6-7):533-40. doi: 10.1016/j.acvd.2009.04.004. Epub 2009 Jul 9.
Percutaneous closure of large persistent ductus arteriosus using the Amplatzer duct occluder is an alternative to surgery. However, this device is not recommended in infants weighing less than 6 kg.
To evaluate the safety and effectiveness of this procedure in low-body-weight infants.
We reviewed retrospectively data for infants weighing less or equal to 6 kg who underwent percutaneous closure of significant persistent ductus arteriosus using the Amplatzer duct occluder in France between 1998 and 2007.
Data for 58 patients (mean weight: 5 kg, range: 3.4-6; mean age: 5.5 months, range: 2.1-15.3) were reviewed. Mean angiographic persistent ductus arteriosus minimal diameter was 3.7 mm (range: 1-7.5). Implantation of the Amplatzer duct occluder was successful in 89.7% of cases. In six (10.3%) patients, the device was not implanted because it would have led to significant aortic obstruction. One procedure-related death occurred in a 4 kg infant (1.7%). Major and minor complications occurred in 6.9 and 31.0% of patients, respectively. Persistent ductus arteriosus diameter greater than 3.7 mm, type C (tubular shape) and diameter/patient weight ratio greater than 0.91 were significantly associated with an unsuccessful procedure and/or major complications. During a median 10-month follow-up, no late device embolization occurred.
Although percutaneous closure of significant persistent ductus arteriosus with the Amplatzer duct occluder is effective in low-body-weight infants, the level and severity of complications indicate surgery as first-line treatment, at least until further studies are done to assess the safety and effectiveness of the new Amplatzer duct occluder II in low-body-weight infants.
使用Amplatzer动脉导管封堵器经皮闭合大型动脉导管未闭是手术的一种替代方法。然而,不建议在体重小于6kg的婴儿中使用该装置。
评估该手术在低体重婴儿中的安全性和有效性。
我们回顾性分析了1998年至2007年期间在法国使用Amplatzer动脉导管封堵器对体重小于或等于6kg的婴儿进行经皮闭合大型动脉导管未闭的资料。
共回顾了58例患者的资料(平均体重:5kg,范围:3.4 - 6kg;平均年龄:5.5个月,范围:2.1 - 15.3个月)。动脉导管未闭造影最小直径平均为3.7mm(范围:1 - 7.5mm)。Amplatzer动脉导管封堵器植入成功率为89.7%。6例(10.3%)患者未植入该装置,因为这会导致严重的主动脉梗阻。1例4kg婴儿发生了1例与手术相关的死亡(1.7%)。主要和次要并发症分别发生在6.9%和31.0%的患者中。动脉导管未闭直径大于3.7mm、C型(管状)以及直径/患者体重比大于0.91与手术失败和/或主要并发症显著相关。在中位10个月的随访期间,未发生晚期装置栓塞。
尽管使用Amplatzer动脉导管封堵器经皮闭合大型动脉导管未闭在低体重婴儿中是有效的,但并发症的程度和严重性表明手术应作为一线治疗方法,至少在对新型Amplatzer动脉导管封堵器II在低体重婴儿中的安全性和有效性进行进一步研究之前如此。